CA - Medexus expects FY23 record revenue of $107M-$108M
2023-04-11 07:40:26 ET
- Medexus Pharmaceuticals ( OTCQX:MEDXF ) reports preliminary revenue FY23 estimates to be $107-$108M, representing record annual revenue and a year-over-year increase of at least 39.5%.
- Annual revenue of $107-$108M implies total revenue between $28M and $28.5M for fiscal Q4 2023, representing a year-over-year increase of at least 38.1%.
- Key highlights for fiscal Q4 2023 to include
- IXINITY: Continuing positive trend in sales, with fiscal Q4 2023 reflecting the best quarter of fiscal year 2023 for new patient conversions on top of a stable, existing base of patients.
- Rasuvo: Continuing strong performance and maintenance of the product’s leading position in the moderately-growing US branded methotrexate market with a highly efficient allocation of sales force resources.
- Rupall: Continuing strong demand growth reflecting successful execution of the company’s sales and marketing initiatives and sustaining the product’s strong performance over the six years since launch.
- Gleolan: Continuing positive trend in US sales, with fiscal Q4 2023 including the best month of fiscal year 2023, reflecting successful execution of the company’s sales and marketing initiatives to date.
- Source: Press Release
For further details see:
Medexus expects FY23 record revenue of $107M-$108M